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TO THE EDITOR
It has been suggested that psoriasis
vulgaris (PV) is a multifactorial disease
and that environmental factors may
trigger PV in genetically susceptible
individuals (Elder et al., 2001; Lebwohl,
2003). At the PSORS1 locus on chromo-
some 6p21.3, the human leukocyte
antigen (HLA)-Cw*0602 allele strongly
associates to susceptibility to psoriasis
in various populations (Mallon et al.,
1999; Zhang et al., 2002). Aside from
HLA-C, the implication of natural killer
and natural killer-T (NK/NKT) cells in
PV and psoriatic arthritis (PA) has also
drawn much attention recently (Martin
et al., 2002; Holm et al., 2005). NK/
NKT cells were present in chronic
psoriatic plaques and the NK/NKT cell
line was shown to induce psoriasis in a
severe combined immunodeficient
mouse model (Nickoloff et al., 2000).
NK/NKT cell function is regulated by
activating and inhibitory receptors pre-
sent on the cell surface. Among them,
the killer cell immunoglobulin-like re-
ceptor (KIR) is the major molecule
recognizing HLA-C and is encoded by
the KIR gene family clustered on
chromosome 19q13.4. KIRs include
activating KIRs such as KIR2DS and
inhibitory KIRs such as KIR2DL.
KIR2DS1 can recognize group 2 HLA-
C including HLA-Cw2, -Cw4, -Cw5,
-Cw6, and related alleles which carry
lysine at amino acid 80 (Lys80). On the
other hand, KIR2DS2 can recognize
group 1 HLA-C such as HLA-Cw1,
-Cw3, -Cw7, –Cw8, and related alleles
which carry Asn80. KIR2DS1,
KIR2DS2, and KIR2DL5 have been
associated with PA and PV (Luszczek
et al., 2004; Suzuki et al., 2004;
Williams et al., 2005). Furthermore,
subjects who are homozygous for
HLA-Cw group 1 or 2 and positive for
KIR2DS1 and/or KIR2DS2 are found to
be most susceptible to developing PA
(Nelson et al., 2004), and patients with
guttate psoriasis were associated with a
distinct HLA-C/KIR genotype profile
(Holm et al., 2005).
In this study, we investigated the
association of the KIR genes (KIR2DS1,
KIR2DS2, KIR2DL1, KIR2DL2, and
KIR2DL5) with PV in 178 Chinese
patients with PV and 203 control
subjects in Taiwan. All participants
gave their written informed consent
before enrolling in the study. The study
was carried out with the approval of the
institutional review board of the hospi-
tal and conducted according to the
Declaration of Helsinki Principles. The
178 psoriasis patients included 125
males and 53 females with a mean
age of 55.9 years (range, 7–87 years);
the predominance of male PV patients
in Chinese has also been reported in a
previous study (Chen et al., 2003).
Ninety-two patients (51.7%) had an
onset of psoriasis before the age of
40 years (early-onset psoriasis) and 86
patients (48.3%) had an onset at age 40
years or older (late-onset psoriasis).
Sixteen (9%) of these patients reported
a family history of PV. The control
group comprised 203 healthy indivi-
duals (141 males and 62 females with a
mean age of 53.9 years (range, 18–77
years)) and included voluntary blood
donors, hospital staff, and medical
students. Genotyping for KIR2DS1,
KIR2DS2, KIR2DL1, KIR2DL2, and
KIR2DL5 was detected by PCR with
sequence-specific primers (Gomez-
Lozano and Vilches, 2002) with an inter-
nal positive control included in each
PCR reaction. Genotyping for HLA-
Cw*0602 was also carried out using
HLA Typing Kits (Lifecodes, Stamford,
CT) and confirmed by sequence-based
typing method (Chang et al., 2004). The
differences of the allele frequencies
between the case and control subjects
were assessed using w2 test or Fisher’s
exact test. Odds ratios, confidence
intervals, and significance values were
calculated using the Epi Info 2000
(CDC, Atlanta, GA).
As shown in Table 1, the genotype
frequencies of activating KIRs (KIR2DS1
and KIR2DS2) and inhibitory KIRs
(KIR2DL1, KIR2DL2, and KIR2DL5)
were similar between the PV patients
and the controls. Therefore, KIR2DS1, a
major susceptibility gene to PV found in
the Caucasian and Japanese popula-
tions, was not a risk gene in the Chinese
population; in fact, the KIR2DS1 fre-
quency in our PV patients was even
Abbreviations: HLA, human leukocyte antigen; KIR, killer cell immunoglobulin-like receptor;
PA, psoriatic arthritis; PV, psoriasis vulgaris
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lower than that in controls. With regard
to the HLA-Cw*0602, it was a major
susceptibility allele in our Chinese
patients and the association was stron-
ger in early-onset PV patients (41.3 vs
12.3%, odds ratio¼5.01, Po107). A
previous study suggested that the sus-
ceptibility to PA was determined by the
overall balance of activating and in-
hibitory composite KIR-HLA genotypes
and HLA-Cw group 1 or 2 homozygo-
sity was associated with increased
risk of developing PA (Nelson et al.,
2004). However, in our study, only
early-onset PV patients were more
likely to be HLA-Cw group hetero-
zygotes (47.8 vs 30.5%, P¼0.006)
(Table 2), which was due to more
HLA-Cw*0602 heterozygotes in early-
onset PV patients. If the NK/NKT cells
activation threshold was predicted ac-
cording to the combination of activat-
ing as well as inhibiting KIR receptors
and their corresponding HLA-C ligands
as previously described (Holm et al.,
2005) (Table 3), and classified as excess
activation, balanced, excess inhibition
and undetermined, the subjects with
excess inhibition were more common
in psoriasis patients (Table 2). This was
also related to their HLA-Cw*0602
status because individuals carrying
HLA-Cw*0602 were more likely to
be classified as excess inhibition class.
If the KIR2DS1/S2 genotype frequen-
cies were compared between the
patients and controls according to
the HLA-Cw*0602 status, no associa-
tion with KIR genes was found either
(Table 4).
Given that the prevalence rate of
psoriasis and the frequencies of HLA-
Cw*0602 in Chinese were lower than
that detected in the Caucasians, we
hypothesized that KIR genes might be
an important PV risk genes in Chinese
as reported in the Japanese population.
However, the genotype frequencies of
KIR2DS1, KIR2DS2, KIR2DL5, and
HLA-Cw group homozygotes were si-
milar between the PV patients and the
controls. In spite of a higher proportion
of subjects with excess inhibition NK/
NKT cell response in the psoriasis
group, it could be related to their
HLA-Cw*0602 status. Although our
results do not support an indepen-
dent effect of KIR genes in psoriasis,
they suggest interaction with HLA-Cw6,
which will imply that KIRs are actually
important in psoriasis pathogenesis.
In conclusion, our results indicate
that KIR genes are not independent PV
susceptibility genes in Chinese. Further
studies are needed to investigate the
role of KIRs in psoriasis pathogenesis.
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Table 1. Genotype frequencies of KIR genes and HLA-Cw*0602
in patients and controls
Gene Patients1 Control subjects P-value
KIR2DS1 All patients 30.9% (55/178) 33% (67/203) 0.74
Early-onset patients 27.2% (25/92) — 0.39
KIR2DS2 All patients 18% (32/178) 20.2% (41/203) 0.68
Early-onset patients 19.6% (18/92) — 0.97
KIR2DL1 All patients 99% (177/178) 100% (203/203) 0.47
Early-onset patients 100% (92/92) — —
KIR2DL2 All patients 20.8% (37/178) 19.2% (39/203) 0.8
Early-onset patients 20.7% (19/92) — 0.9
KIR2DL5 All patients 37.7% (67/178) 40.4% (82/203) 0.66
Early-onset patients 33.7% (31/92) — 0.33
HLA-Cw*0602 All patients 30.9% (55/178) 12.3% (25/203) 0.000016
Early-onset patients 41.3% (38/92) — (o107)2
1The genotype frequencies are compared between all 178 PV patients (or 92 early-onset patients) and
203 controls.
2Odds ratio=5.01 (2.67–9.44).
Table 2. HLA-Cw group zygosity and predicted NK/NKT cell action
threshold in patients and controls
Group
All patients
(n=178)
Early-onset
patients (n=92)
Controls
(n=203)
Cw group zygosity
Group 1 homozygotes 57.9% (103) 46.7% (43) 66.5% (135)
Group 2 homozygotes 5.6% (10) 5.4% (5) 3% (6)
Group heterozygotes 36.5% (65) 47.8% (44)1 30.5% (62)
Predicted NK/NKT cells action threshold 2
Excess activation 0% (0) 0% (0) 1.5% (3)
Balanced 24.2% (43) 21.7% (20) 27.6% (56)
Excess inhibition 30.9% (55)3 40.2% (37)4 20.7% (42)
Undetermined 44.9% (80) 38% (35) 50.3% (102)
1Odds ratio=2.11 (1.41–3.16), P=0.006.
2The NK/NKT cells response is predicted according to activating and inhibiting KIR receptors and
corresponding HLA-C ligands as described before (Holm et al., 2005).
3Odds ratio=1.71 (1.05–2.8), P=0.03.
4Odds ratio=2.58 (1.45–4.57), P=0.00076.
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TO THE EDITOR
Peeling skin syndrome type B (PSS-type
B, MIN 270300) is a congenital skin
disease associated with continual skin
peeling and ichthyotic erythroderma,
known to display various clinical simi-
larities with Netherton syndrome (NS,
caused by genetic defects of serine pro-
tease inhibitor Kazal-type5 (SPINK5),
MIN 256500) (Wile, 1924; Traupe,
1989; Magert et al., 1999; Chavanas
et al., 2000). Human tissue kallikreins
are a family of 15 trypsin- or chymo-
trypsin-like secreted serine proteases
(hK1–hK15) found in a variety of tissues
(Yousef and Diamandis, 2001). At least
eight different hKs have been identi-
fied in the stratum corneum (SC) and
sweat as desquamation-related pro-
teases (Komatsu et al., 2005b, 2006).
Here, we aimed (1) to clarify the patho-
genesis of PSS-type B, (2) to elucidate
the relationship between PSS-type B
and hK expression, and (3) to explain
the reason for the clinical similarities
between PSS-type B and NS.
Informed consent was obtained from
all patients, their parents, and normal
volunteers, and our studies were per-
formed according to the Declaration of
Helsinki Principles. The Medical Ethics
Committee of the Graduate School
of Medical Science, School of
Medicine, Kanazawa University and
Juntendo University, School of Medicine,
approved all described studies. Two
unrelated 8-year-old female Japanese
patients (Patient M and Patient K) were
studied (Figure S1 and Table S1).
Patients M and K were born with ery-
throderma accompanied by scaling and
their lesions have shown no improve-
ment to date. Patient M suffered sig-
nificant growth retardation (o2 SD)
since the age of 1 and occasional
herpes simplex infections in her peri-
oral region. Both patients experience
severe pruritus, temperature instability,
and low sweat secretion. Patient M
exhibited overabsorption of topical
agents from skin, which is also obser-
ved in NS (Smith et al., 1995; Allen
et al., 2001). Asthma attacks were
experienced in Patient M but no aller-
gic diseases were apparent in Patient K.
Both patients displayed eosinophilia
and elevated serum IgE levels. As many
clinical manifestations observed in
the patients are common between NS
and PSS-type B (Traupe, 1989; Judge
et al., 1994; Griffiths et al., 1998),
SPINK5 gene mutation analysis by
genomic polymerase chain reaction
and sequencing was performed for both
patients using specific primers (Komat-
su et al., 2002). However, no gene
mutations were detected in both pa-
tients; therefore, NS was ruled out,
leaving PSS-type B as the most likely
diagnosis.
Pathologically, the patients showed
an absence of the SC or a few layers of
parakeratosis, which tended to be
separated from the stratum granulosum,
psoriasisforme acanthosis, and peri-
vascular infiltration with mononuclear
leukocytes (Figure S2).
Immunohistochemistry for hK6, hK8,
hK13, and SPINK5 protein showed that
they were mainly expressed in the
stratum granulosum and SC in normal
epidermis (Figure 1). In both patients,
the hKs and SPINK5 protein expressions
were similarly distributed, and their
stainings were deeply expanded into
the lower epidermis compared with
those in normal skin. It is known that
the skin of NS patients shows absent or
only faint staining against the same anti-
SPINK5 protein antibody (Raghunath
et al., 2004). Consequently, Patients M
and K are unlikely to suffer from NS.
In the SC of both Patients M and K,
all hK concentrations studied by ELISA
were dramatically higher than those in
the normal SC samples (Table 1a). The
elevation of minor skin hKs (e.g., hK10,
hK6, and hK13;o1.0 ng/mg dry weight
for normal subjects) were prominent in
the SC of the patients (Table 1a). In the
serum, hK6, hK7, hK8, hK10, and hK13
concentrations were significantly ele-
vated in the patients (Table 1b).
SC trypsin-like serine protease enzy-
matic activity examined using Boc-
Pro-Phe-Arg-AMC (PFR-) as a substrate,
and plasmin-like (for Boc-Val-Leu-Lys-
AMC; VLK-) and furin-like (for Pyr-
Arg-Thr-Lys-Arg-AMC; R-KR-) activities
were significantly elevated, whereas
trypsin-like (for Boc-Phe-Ser-Arg-AMC;
FSR-) and chymotrypsin-like (for MeO-
Suc-Arg-Pro-Tyr-pNA-HCl; RPY-) activ-
ities showed only mild elevations in
both patients (Table 1c).
Abbreviations: AMC, 7-amino-4-methyl-commarin; hK, kallikrein protein; NS, Netherton syndrome;
pNA, para-nitroanilide; PSS, peeling skin syndrome; SC, stratum corneum; SPINK5, serine protease
inhibitor Kazal-type 5
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